By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539


SEARCH JOBS
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Key Statistics


Email: hr@halozyme.com
Ownership: Public

Web Site: Halozyme
Employees: 152
Symbol: HALO
 









Company News
Halozyme (HALO) To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call 2/2/2016 7:00:10 AM
Halozyme (HALO) Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE Technology 1/21/2016 6:56:27 AM
Halozyme (HALO) Provides Key Program Updates, 2016 Financial Guidance At 34th Annual J.P. Morgan Healthcare Conference 1/11/2016 11:40:10 AM
Halozyme (HALO) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/6/2016 10:36:39 AM
Halozyme (HALO) Enters Into Agreement For $150 Million Non-Dilutive Royalty-Backed Debt Financing 1/4/2016 7:30:11 AM
Halozyme (HALO), Eli Lilly (LLY) Strike $825 Million Global Collaboration And Licensing Pact 12/21/2015 6:49:02 AM
Halozyme (HALO) And Eisai Inc. (ESALF.PK) To Present Data Evaluating The Antitumor Effects Of PEGPH20 In Combination With Eribulin Mesylate In Preclinical Breast Cancer Models 12/9/2015 7:48:32 AM
Halozyme (HALO) To Present At Upcoming Healthcare Conferences 11/25/2015 6:48:20 AM
SoCal's Halozyme (HALO) To Expand With A Satellite Office In San Francisco 11/18/2015 6:22:06 AM
Halozyme (HALO) Reports Third Quarter 2015 Financial Results 11/10/2015 8:08:17 AM
12345678910...
//-->